Non-Small Cell Lung Cancer Coverage from Every Angle

FDA Brief: Pemetrexed Injection Receives FDA Approval for Lung Cancer

By: JNCCN 360 Staff
Posted: Wednesday, September 9, 2020

The U.S. Food and Drug Administration (FDA) recently approved an injectable form of pemetrexed for patients with recurrent or metastatic nonsquamous non–small cell lung cancer with a history of chemotherapy. The drug is indicated as a single-agent treatment after four cycles of first-line platinum-based chemotherapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.